皇冠体育app

/ Companies

GSK puts 皇冠体育app corruption case behind it, forms new business model

By Cecily Liu (chinadaily.com.cn) Updated: 2015-10-22 20:17

GSK puts 皇冠体育app corruption case behind it, forms new business model

The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai in this July 12, 2013 file photo.[Photo/Agencies]

GlaxoSmithKline emerged from its corruption scandal in 皇冠体育app in 2013 to form a new business model in the country and is committed to further expansion there, chief executive officer Andrew Witty told 皇冠体育app Daily in London on Wednesday in an exclusive interview.

"We think it's a very sad and disappointing experience, but we've reacted constructively and learnt many things. And now we understand 皇冠体育app better, we have a new commercial model and incentive system, which is in step with the expectations of the Chinese government," Witty said.

In 2013, GSK was found by the Chinese authorities to be bribing doctors to prescribe its drugs to patients, and after a court trial the company was made to pay a $489 million fine in 2014.

Witty said that GSK has since developed a commercial model with improved technology and transparency.

The transparency of the model allows GSK to monitor its sales staff to make sure no bribe is paid to doctors, and the continuously improving technology allows doctors to obtain much more information about GSK drugs to aid their decision making process when prescribing medicine.

"We've made it clear to the doctors in 皇冠体育app about our changes and have spent a great deal of time to explain to them the reasons for us making the changes. We have received a lot of understanding and appreciation from doctors about our approach," Witty said.

As well, GSK has invested in continuously improving technology to reduce the cost of the medicine, Witty said.

Speaking about 皇冠体育app's healthcare market environment, Witty said that 皇冠体育app is a country that it takes time to understand, just like any other country, and understanding 皇冠体育app encompasses its economic policies, economic direction and regulation.

He said that "GSK is lucky to be a guest of 皇冠体育app" and will fulfill its responsibility to deliver the medicine that are up to expectations.

GSK also announced on Wednesday that it will invest 2 million pounds in a 3 year partnership with the National Health and Family Planning Commission of 皇冠体育app to train seven thousand Chinese doctors in the diagnosis and treatment of Hepatitis B.

Witty said that this investment reaffirms GSK's long term commitment to serving 皇冠体育app and the healthcare needs of patients in the country.

Hepatitis B is a high priority in 皇冠体育app, with about 20 million sufferers across the country remaining untreated.

"We think it is important that we're doing the training in partnership with the Chinese government, so that we can make sure what we have invested in will help to address issues that are of real importance to 皇冠体育app," said Witty.

He said that the Hepatitis B investment is similar to GSK's investment into training Chinese doctors in the treatment of respiratory conditions and chronic obstructive pulmonary disease, announced last month, which are also healthcare priority areas identified by the government.

The Hepatitis B program, to be run over three years, and delivered by the Development Center for Medical Science and Technology, National Health and Family planning Commission of 皇冠体育app, will help doctors understand how to diagnose, treat and provide ongoing management to patients with Hepatitis B.

Witty said that 皇冠体育app will remain important to GSK over the long term, in particular because it has a large population, meaning that from a commercial perspective the sales potential is great, and from a research perspective it can provide a valuable environment to develop medicine that GSK can use globally.

GSK was ranked as the world's sixth-largest pharmaceutical company in 2014, with revenue of 23 billion pounds.

GSK has already committed 6 million pounds for public health initiatives in 皇冠体育app over the next five years, with around 4 million being spent on independent GP training, the company said in a statement.

To contact the reporter: [email protected]

Hot Topics

Editor's Picks
...